Balance4Mobility: Walkasins for Peripheral Neuropathy and Balance Problems

This study, called Balance4Mobility, is looking at whether a device called Walkasins can help people with peripheral neuropathy (nerve damage that can cause weakness, numbness, and pain) improve their balance. Walkasins are external devices worn on the lower leg that aim to replace some of the nerve function needed for feeling foot pressure during standing and walking. The main goal is to see if using Walkasins daily for six months helps people become more aware of where their feet are placed. Researchers will compare people using Walkasins to a group not using them, by looking at how they perform on walking and balance tests. If you are 55 or older, have a diagnosis of peripheral neuropathy, and can walk without an assistive device, you might be able to join. The study's current status is unclear, and it plans to enroll 200 participants.

Study design
This is an interventional study with an unclear status, planning to enroll 200 participants. Researchers will compare people using Walkasins to a control group not using them.
What's involved
Participants will answer questions about their medical history and balance, and complete standing and walking tests at various times over 52 weeks. They will also watch an educational video and receive handouts on fall prevention.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 52 weeks, with various assessments throughout this period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06959277

Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems

Recruiting
NAAges 55+InterventionalTreatment
RxFunction Inc.
~200 participants
Updated 2026-07-14 on ClinicalTrials.gov
What's tested:WalkasinsFall Prevention Training

At a glance

Recruiting sites
3 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Functional Gait Assessment (FGA)
Measured over Baseline, Week 10, Week 26, Week 36 (Control Group), and Week 52
+2 more outcomes measured
Peripheral Neuropathies
Peripheral Neuropathy Due to Chemotherapy
Peripheral Neuropathy With Type 2 Diabetes
Balance Control in Elderly
Gait Disorders
6 sites across 6 states
Arizona1
Massachusetts1
Minnesota1
New York1
Pennsylvania1
Texas1
  • Lars Oddsson, PhD · STUDY_DIRECTOR · RxFunction Inc.

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Able to understand and provide informed consent for him or herself
Age 55 and older, male or female
Able to complete all functional outcome measures without the use of an assistive device
Clinical diagnosis of peripheral neuropathy prior to participating in the study as documented in the participant's medical record or by physician's note. Individuals with chemo-induced peripheral neuropathy must be at least one-year post-chemotherapy, indicating that their PN has become a chronic condition.
Self-reported gait and balance problems
Foot size that allows the Walkasins to function appropriately
Willing to use the Walkasins device as recommended

Exclusion

Ability to stand on one leg for at least 30 seconds (If the person can stand for at least 30 seconds, he/she is excluded because his/her balance is likely not impaired enough to benefit from Walkasins.)
Self-reported acute thrombophlebitis, including deep vein thrombosis
Self-reported severe peripheral vascular disease
Untreated lymphedema
Untreated lesion of any kind, swelling, infection, inflamed area of skin or eruptions on the lower leg near product use
Self-reported, untreated fractures in the foot and ankle
Other neurological or musculoskeletal conditions that moderately or severely impact walking
Use of ankle-foot orthosis for ambulation that prevents donning of Walkasins
Weight of more than 300 pounds
Inability to perceive vibration from Walkasins Haptic Module
  • Functional Gait Assessment (FGA)Baseline, Week 10, Week 26, Week 36 (Control Group), and Week 52

    The Functional Gait Assessment (FGA) is a 10-item scale that measures postural stability while individuals perform walking tasks that are scored from 0 to 3 (3 = normal, 2 = mild impairment, 1 = moderate impairment, 0 = severe impairment). Scores range from a minimum of 0 to a maximum of 30. Higher scores indicate better postural stability.

  • Patient-Specific Functional Scale (PSFS)Baseline, Week 5, Week 10, Week 18, Week 26, Week 31, Week 36, Week 41, Week 46, and Week 52

    The PSFS asks patients to define up to five specific tasks that they have difficulty with or are unable to perform because of their physical injury or disability. Some research studies adapt the PSFS by asking participants to list three tasks rather than five, which is the plan for this study. The patients then rate their difficulty in performing those tasks on a scale of 0 to 10 with 0 meaning "unable to perform activity" to 10 meaning "able to perform activity at the same level as before injury or problem." The ratings for the three activities are averaged. Higher scores indicate greater ability to perform the activity.

  • PROMIS® PROWalkBaseline, Week 5, Week 10, Week 18, Week 26, Week 31, Week 36, Week 41, Week 46, and Week 52

    Eight items that have the most relevance for measuring change in individuals who have received Walkasins were selected from the 165 items comprising the PROMIS Item Bank v2.0 - Physical Function. Specifically, the selected items measure an individual's ability to perform various activities that involve upright mobility (balance, standing, and walking). Participants rate the eight items on a scale of 1 to 5; the raw scores are converted to T-scores for comparison to national norms.